PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

DOACs Linked to Lower Stroke and Bleeding in Elderly AF

DOACapixabanrivaroxabandabigatranwarfarinatrial fibrillationelderlystroke preventionintracranial hemorrhagegastrointestinal bleedinganticoagulationretrospective cohortreal-world evidence Anticoagulation / Hematology
Also in Geriatrics

Background Information

DOACs safely reduce stroke risk in elderly AF patients.

Direct oral anticoagulants (DOACs) are increasingly used in elderly patients with atrial fibrillation (AF), offering a safer alternative to warfarin. DOACs were associated with reduced stroke and gastrointestinal bleeding (GIB) risks compared to non-users: stroke risk reduced by 29% and GIB by 19%. The study confirms DOACs as a safer option than warfarin in elderly AF patients, reducing stroke and gastrointestinal bleeding risks without increasing intracranial hemorrhage (ICH) risk. DOACs are a safer, effective option for managing atrial fibrillation in elderly patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Alnsasra H, Tsaban G, Ostrovsky D, Livne N, Filderman B, Henkin Y, Iakobishvili Z, Arnson Y, Eisen A, Weisband Y, Schliamser J, Haim M

Citation: Alnsasra H, Tsaban G, Ostrovsky D, et al. Direct oral anticoagulants in elderly patients with atrial fibrillation: a decade-long nationwide retrospective cohort study. BMJ open. 2026;16(8):e121683. doi:10.1136/bmjopen-2026-121683

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.